Reuters reported quoting a source with the Drug Controller General of India (DCGI). Aurobindo Pharma Ltd wants to discontinue a late-stage trial of molnupiravir in moderate Covid-19 patients, the regulator's expert committee said on Friday. "There is no significant efficacy against moderate Covid and the effective efficacy is towards mild cases," the source said on condition of anonymity due to the sensitive nature of the discussions.
The regulator and health ministry did not immediately respond to a request seeking comment. In an interim analysis of a late-stage clinical trial, molnupiravir is said to have reduced the risk of hospitalisation or death by 50%, Merck and partner Ridgeback Biotherapeutics LP announced earlier.